His course seemed very clear now. He would go back to Washington, file a committee report, and stay there at his proper job. No one would really expect much from his very first Senate assignment. He had more than enough material for a devastating exposé of the Collaboratory’s internal workings. If that wasn’t in the cards, he could play up the Collaboratory’s positive aspects: the profound effect of biotech spinoffs on the regional economy, for instance. He could trumpet the futuristic glamour of the next big federal breakthrough: high-tech industrial neuroscience. Whatever they wanted to hear.